Review



primary antibodies against col3a1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech primary antibodies against col3a1
    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, <t>COL3A1</t> and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Primary Antibodies Against Col3a1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 536 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+col3a1/pm40241143-121-0-4?v=Proteintech
    Average 96 stars, based on 536 article reviews
    primary antibodies against col3a1 - by Bioz Stars, 2026-07
    96/100 stars

    Images

    1) Product Images from "CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression."

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    Journal: Journal of translational medicine

    doi: 10.1186/s12967-025-06325-5

    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Figure Legend Snippet: Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs

    Techniques Used: Expressing

    Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05
    Figure Legend Snippet: Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05

    Techniques Used: Expressing

    Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001
    Figure Legend Snippet: Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001

    Techniques Used: Control, Expressing



    Similar Products

    primary antibody against collagen type 3  (Novus Biologicals)
    95
    Novus Biologicals primary antibody against collagen type 3
    Primary Antibody Against Collagen Type 3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+col3a1/pm40179080-72-0-11?v=Novus+Biologicals
    Average 95 stars, based on 1 article reviews
    primary antibody against collagen type 3 - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    primary antibodies against col3a1  (Proteintech)
    96
    Proteintech primary antibodies against col3a1
    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, <t>COL3A1</t> and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Primary Antibodies Against Col3a1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+col3a1/pm40241143-121-0-4?v=Proteintech
    Average 96 stars, based on 1 article reviews
    primary antibodies against col3a1 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    primary antibodies against α-sma, col1a1, col3a1, ctgf  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc primary antibodies against α-sma, col1a1, col3a1, ctgf
    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, <t>COL3A1</t> and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Primary Antibodies Against α Sma, Col1a1, Col3a1, Ctgf, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+col3a1/10__14218_slash_jcth__2021__00511-51-22-23?v=Cell+Signaling+Technology+Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against α-sma, col1a1, col3a1, ctgf - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    primary antibodies against col3a1  (Novus Biologicals)
    90
    Novus Biologicals primary antibodies against col3a1
    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, <t>COL3A1</t> and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Primary Antibodies Against Col3a1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/primary+antibodies+against+col3a1/10__1530_slash_jme___17___0215-78-20-26?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    primary antibodies against col3a1 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Expressing

    Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Expressing

    Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Control, Expressing